CPC A61K 9/107 (2013.01) [A61K 31/12 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/704 (2013.01); A61K 33/243 (2019.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01)] | 20 Claims |
1. An emulsion formulation comprising:
(a) 1 to 15 wt. % of polyethylene glycol (15)-hydroxystearate,
(b) 0.3 to 10 wt. % of polyglyceryl-3 oleate,
(c) at least one anti-cancer drug selected from oxaliplatin, cisplatin, doxorubicin, or paclitaxel,
(d) optionally, polysorbate, and
(e) water,
wherein the emulsion is an oil-in-water micro- or nanoemulsion and all percentages by weight are based on a total weight of the emulsion formulation.
|